- GlaxoSmithKline (NYSE:GSK) and SK bioscience announced the initiation of a global Phase 3 trial for GBP510, SK’s COVID-19 vaccine candidate that uses the pandemic adjuvant from GSK.
- The randomized, active-controlled trial, expected to enroll about 4,000 trial participants, will be designed to evaluate GBP510 compared to the COVID-19 vaccine developed by AstraZeneca (NASDAQ:AZN) and Oxford University.
- The results from the study are anticipated in H1 2022, and subject to regulatory approval with positive data, GBP510 will be available globally through the COVAX facility.
- The clinical advancement of GBP510 is based on positive interim Phase 1/2 results where the self-assembled nanoparticle vaccine candidate led to strong antibody responses with a 100% seroconversion rate in all subjects.
- In addition to its partnership with SK bioscience, GlaxoSmithKline (GSK) has teamed up with Sanofi (NASDAQ:SNY) for a large late-stage trial for an adjuvanted recombinant-protein COVID-19 vaccine candidate.